Zhang et al reported a model for evaluating a patient with chronic myeloid leukemia (CML) treated initially with imatinib. The authors are from Peking University, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, and Imperial College London.
Patien selection: chronic myeloid leukemia (CML treated with imatinib
Parameters:
(1) WBC count in 10^9/L
(2) hemoglobin concentration in g/L
(3) percent basophils in the differential count
(4) European Treatment and Outcome Study for CML Long-Term Survival (ELTS) risk score
Parameter
Finding
Points
WBC count
< 120 * 10^9/L
0
>= 120 * 10^9/L
1
hemoglobin
>= 115 g/L
0
< 115 g/L
1
percent basophils
< 12%
0
>= 12%
1
ELTS risk score
not high-risk
0
high risk
2
total score =
= SUM(points for all of the parameters)
Interpretation:
• minimum score: 0
• maximum score: 5
Total Score
Risk Group
-
very low
1
low
2
intermediate
3
high
>= 4
very high
Performance:
• The area under the ROC curves were 0.78 to 0.85.
To read more or access our algorithms and calculators, please log in or register.
